Repligen reported $58.99M in EBIT for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Agilent A:US $ 434M 50M
Align Technology ALGN:US $ 188.2M 9.89M
Biomarin Pharmaceutical BMRN:US $ 39.15M 9.82M
Bristol Myers Squibb BMY:US $ 3197M 9M
Bruker BRKR:US $ 86M 17.4M
Catalent CTLT:US $ 261M 45M
Charles River Laboratories CRL:US $ 187.41M 38.63M
Danaher DHR:US $ 2205M 33M
Exact Sciences EXAS:US $ -152993000 23.99M
General Electric GE:US $ 1090M 587M
Henry Schein HSIC:US $ 223M 21M
Illumina ILMN:US $ 30M 154M
IQVIA Holdings Inc IQV:US $ 482M 20M
Mettler Toledo International MTD:US $ 271.73M 42.88M
Myriad Genetics MYGN:US $ -17800000 2.9M
Pacific Biosciences Of California PACB:US $ -67969000 9.55M
Patterson Companies PDCO:US $ 34.84M 37.99M
Peregrine Pharmaceuticals PPHM:US $ 2.74M 1.67M
Perkinelmer PKI:US $ 300.97M 12.24M
Pfizer PFE:US $ 12099M 2104M
Repligen RGEN:US $ 58.99M 1.79M
Thermo Fisher Scientific TMO:US $ 2025M 798M
Waters WAT:US $ 199.65M 4.18M
West Pharmaceutical Services WST:US $ 225.5M 36.9M